Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Gossamer Bio, Inc.NASDAQ: GOSS

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns negative

Q1 FY2026 other income / expenses was -$1.8M, compared with $172K a year earlier. Trailing-twelve-month other income / expenses was -$1.7M.

Context

  • Other income / expenses amounted to 14.9% of revenue in FY2025, up 11.1 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$1.8M or moves back toward the trailing-twelve-month quarterly average of -$424.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.8M-39.8% QoQ
Last fiscal yearDec 2025
-$7.21M-268.2% YoY
LTMMar 2026
-$1.7M-138.4% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1145.3%——
1 year-268.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(7.21M) USD
Year-over-year change
-268.2%

Other Income / Expenses vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 other income / expenses of -$1.7M is the 6th highest of the 9 companies compared; the peer median is $1.27M.
  • Its year-over-year change of -138.4% is the 6th highest of 8, against a peer median of -10.8%.
  • Other income / expenses amounts to 3.1% of revenue for GOSS, versus a peer median of 11.9%.
GOSS Competitors Peer median
Other Income / Expenses for GOSS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$20.28M -10.8%—35.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$18.65M -30.6%+97.1%21.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$16.66M +19.9%+94.7%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.76M +136.9%——
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-$1.21M ——1.0%
GOSSGossamer Bio, Inc.LTM Mar 2026-$1.7M -138.4%—3.1%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-$1.86M -1250.0%—2.7%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026-$2.61M +55.1%—0.9%
RGNXREGENXBIO Inc.LTM Mar 2026-$33.33M -9907.5%—37.9%
Peer median (excluding GOSS) $1.27M-10.8%+95.9%11.9%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000114.7M48.47M
Cost of Revenue00001M
Gross Profit000114.7M47.47M
Gross Margin———100.0%97.9%
Research & Development170.27M170.92M135.3M138.49M174.09M
Selling, General & Admin45.78M47.61M38.46M36.13M37.63M
Operating Expenses216.12M218.59M183.76M174.62M210.72M
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
EBITDA(209.4M)(211.07M)(161.92M)(39.97M)(158.47M)
EBITDA Margin———-34.8%-326.9%
Operating Income(216.12M)(218.59M)(183.76M)(59.92M)(163.25M)
Operating Margin———-52.2%-336.8%
Interest Income761K1.58M2M1.78M1.97M
Interest Expense19.44M13.88M13.51M11.52M10.99M
Other Income / Expenses(17.88M)(10.79M)3.94M4.28M(7.21M)
Income Before Tax(234M)(229.38M)(179.82M)(55.64M)(170.46M)
Pre-Tax Margin———-48.5%-351.7%
Income Tax Expense000893K(88K)
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Net Margin———-49.3%-351.5%
EPS (Basic)(3.33)(2.84)(0.80)(0.25)(0.75)
EPS (Diluted)(3.33)(2.84)(1.18)(0.25)(0.75)
Weighted Avg Shares74.84M84.57M225.57M226.23M228.52M
Weighted Avg Shares (Diluted)74.84M84.57M225.57M226.23M228.52M

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.